Unknown

Dataset Information

0

Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

ABSTRACT: Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2] conformational specificity and CD4-binding site specificity, respectively) that recapitulate 95% of CH0219 serum neutralization breadth. These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities.

SUBMITTER: Bonsignori M 

PROVIDER: S-EPMC3318651 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

Bonsignori Mattia M   Montefiori David C DC   Wu Xueling X   Chen Xi X   Hwang Kwan-Ki KK   Tsao Chun-Yen CY   Kozink Daniel M DM   Parks Robert J RJ   Tomaras Georgia D GD   Crump John A JA   Kapiga Saidi H SH   Sam Noel E NE   Kwong Peter D PD   Kepler Thomas B TB   Liao Hua-Xin HX   Mascola John R JR   Haynes Barton F BF  

Journal of virology 20120201 8

Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2] conformational specificity and CD4-binding site specificity, respectively) that recapitulate 95% of CH0219 serum neutralization breadth. These data  ...[more]

Similar Datasets

Unknown Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women.
| S-EPMC4816677 | biostudies-literature
Unknown Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
| S-EPMC1900098 | biostudies-literature
Unknown Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects.
| S-EPMC2879344 | biostudies-literature
Unknown Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.
| S-EPMC4125441 | biostudies-literature
Unknown Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
| S-EPMC4890714 | biostudies-literature
Unknown HIV broadly neutralizing antibody targets.
| S-EPMC4437463 | biostudies-literature
Unknown A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.
| S-EPMC7092357 | biostudies-literature
Unknown Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
| S-EPMC2716009 | biostudies-literature
Proteomics Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates
2024-02-26 | MSV000094174 | MassIVE
Unknown Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.
| S-EPMC5987927 | biostudies-literature